A Prospective Randomized Multicenter Trial to Assess Imaging During Follow Up After Radical Surgery of Stage IIb-c and III Cutaneous Malignant Melanoma
Led by Uppsala University · Updated on 2024-12-16
1300
Participants Needed
20
Research Sites
N/A
Total Duration
On this page
AI-Summary
Brief Title
Who Can Participate
AI-Screening
Your Study Journey
Trial Site Locations
Research Team
How is the study designed?
Similar Trials
Frequently Asked Questions
Research Publications
AI-Summary
What this Trial Is About
Researchers are investigating whether regular radiological assessments during follow-up after surgery for high-risk malignant melanoma improve patient survival. The study addresses concerns about the resource demands, potential radiation exposure, and anxiety caused by such imaging, especially given the recent introduction of effective medical treatments for melanoma. There is currently no clear evidence supporting routine imaging in this context.
Participants are randomly assigned to one of two groups. One group follows national guidelines with regular doctor appointments for 3 years, while the other group receives the same follow-up plus additional whole-body CT or PET scans and blood tests at baseline, 6, 12, 24, and 36 months. An interim analysis will be done after 1,000 patients enroll.
During the study, researchers will monitor overall survival at 5 years as the primary outcome. They will also assess quality of life through questionnaires over the 3-year follow-up. Participants will attend scheduled visits for clinical evaluations, imaging, and blood tests, with the study aiming to provide clear evidence about the role of imaging in post-surgical melanoma care.
CONDITIONS
Brief Title
A Randomized Trial to Assess the Role of Imaging During Follow Up After Radical Surgery of High Risk Melanoma
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
At least 18 years of age
Radical surgery for Cutaneous Malignant Melanoma stage IIb-c and III
Sufficient renal function for intravenous contrast scans
You will not qualify if you...
Assessed as unfit to receive treatment if melanoma recurs
Life expectancy less than 2 years due to other serious diseases
Unable or unwilling to provide informed consent
Unable to comply with follow-up program
Participation in other clinical trials affecting follow-up
Other malignancies within past 5 years except certain in situ cancers
Pregnancy or planned pregnancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Evaluation
Duration - 3 years
Participants are assigned to routine follow-up or follow-up with additional radiological assessments including CT or PET scans and blood tests.
5 visits for scans and blood tests at baseline, 6, 12, 24, and 36 months
Long-term Monitoring
Duration - Up to 3 years
Participants continue follow-up with regular doctor's appointments according to national guidelines for ongoing assessment.
Regular doctor’s appointments as per national guidelines
Trial Site Locations
Total: 20 locations
1
Södra Älvsborgs sjukhus
Borås, Sweden
Terminated
2
Mälarsjukhuset Eskilstuna
Eskilstuna, Sweden
Actively Recruiting
3
Falu lasarett
Falun, Sweden
Actively Recruiting
4
Gävle sjukhus
Gävle, Sweden
Actively Recruiting
5
Department of Surgery, Sahlgrenska University Hospital
Physical examinations and whole-body imaging versus physical examinations alone during follow-up after radical surgery of stage IIB-C and III cutaneous malignant melanoma (TRIM): an interim analysis of a multicentre, randomised, phase 3 trial in Sweden.
TRIM study protocol - a prospective randomized multicenter Trial to assess the Role of Imaging during follow-up after radical surgery of stage IIB-C and III cutaneous malignant Melanoma.